General Comments / Chat, page-88

Thankyou very much for this explanation Dr T

I knew also that it was complicated - I recall impression that they were in effect placing the Doxyrubicin in a sort of ‘shroud ‘ - complicated drug delivery system .
For the aim of getting the Doxyrubicin directly more to the cancer cells more , or to seek to bypass the highly deleterious cardiac and other malignant effects .
* To ‘Only ‘ have the Doxyrubicin attack and kill the cancer cells, more - rather than be damaging to human good tissue cells .
But it sounded whacky and fraught to me .

I had not regarded it too much then , as it seemed so extraordinary , & complex design .
And is experimental , and more points to how motivated they are to try to keep doxyrubicin in existence as major drug , rather than have it completely lose favour.
**All to justify Doxyrubicin ongoing , when heart damage cannot and neither should it be ! , anymore ignored .

It is unacceptable already , and oncologists reluctantly have been turning away from Doxyrubicin even though in their hands it has been very good at knocking down a bulk of the cancer in treatment.

Mainly - doxyrubicin has hugely helped to save the patients life .
At least initially... “But .
‘ Longterm heart failure is a pretty big ‘But ‘

Children cannot tolerate it - kills them .
Their heats not strong enough to begin with.

It is sad also - to see a rising incidence of cancers in children . Increasing rates of children’s cancers - reported today in major news .

Not good to hear of bad side effects of this new development drug though - but they have introduced another layer of complexity to try to mitigate effects of a nasty drug with doxyrubicin here .

The chemotherapy drug is only one part in saving the patients lives !
No 1 should be - seek to not harm the patient .

“Above all - Do No Harm “. It’s the no 1 principle in medicine and health. Or should be !

If there is better other alternative- which could be simple to substitute in many cancers - or can be found that exists , then this changes the equation .
Bisantrene is safer in terms of cardiac muscle non- toxicity , and has an advanced pre- history .
Over 40 clinical trials already . Huge amount of data for Bisantrene .
The liposomal Doxyrubicin trials are not as advanced at all as Bisantrene has been .

Your explanations and education as ever , are very much appreciated.